 |
|
|
| |
Pros and Cons of Boosted PI Monotherapy
|
| |
| |
Reported by Jules Levin
EACS Cologne Nov 11-14 2009
Presented in an oral talk by Dr. Jose R Arribas alter the several oral slide presentations on PI monotherapy
HIV UNIT
XV WAC 2004 MoOrB1057. 4th IAS 2007 WEPEB034. J Infect Dis. 2008 15;198:234. JAIDS 2005;40:280-287. AIDS. 2008;11:F1-9. XVI IAC 2006; #TUAB0102. EACS 2009 PS4/5 .J Infect Dis. 2009 15;199:866. AIDS 2007; 21:1309-1315. JAIDS 2007;44:417. EACS 2009 PS4/6. 5th IAS 2009 AIDS 2009 (in press)
Arribas JR. et al., 11th EACS, Madrid, 2007, # PS3/1
Systematic review of boosted PI monotherapy
Bierman WF. AIDS 2009, 22:1-13
Pulido F et al. AIDS. 2008 Jan 11;22(2):F1-9.
Arribas JR. et al., 11th EACS, Madrid, 2007, # PS3/1 OK04
Single Genome Sequencing Analyisis. OK04
Mckinnon J et al. XVII International HIV Drug Resistance Workshop. Sitges Abstract #80
Comparison of Suppressed HIV RNA levels between Treatment Arms by Study Week
McKinnon J et al. AIDS 2006 28;20:2331-5
OK04: Risk factors for loss of virological suppression
Pulido F. Antivir Ther. 2009;14:195-201
Lopinavir monotherapy and CSF replication
Yeh et al. CROI 2007
Canestri A et al. CROI 2009. # 484ª
Yeh et al. 11th EACS. 2007
Cameron DW et al., 14th CROI, Los Angeles, February 2007, Oral#44LB M03-613
Arribas JR. GESIDA 2009. Abstract PO071
EACS Guidelines 2009.
|
| |
|
|
|
|
|
